BioMerieux SA

BIM

Company Profile

  • Business description

    BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (34% of 2023 sales), microbiology (39%), immunoassays (10%), and industrial applications (about 17%). The Amercas account for the largest portion of the firm's revenue (45%), followed by Europe, the Middle East, and Africa (31%), and Asia-Pacific (16%). BioMérieux is headquartered in Marcy-l'Etoile, France.

  • Contact

    Marcy l’Etoile
    Lyon69280
    FRA

    T: +33 478872000

    E: [email protected]

    http://www.biomerieux.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Diagnostics & Research

    Fiscal Year End

    31 December 2025

    Employees

    14,754

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,796.2032.50-0.37%
CAC 407,766.7143.240.56%
DAX 4024,206.91133.240.55%
Dow JONES (US)44,240.76165.60-0.37%
FTSE 1008,854.1847.650.54%
HKSE23,970.39177.68-0.74%
NASDAQ20,418.465.950.03%
Nikkei 22539,747.5358.720.15%
NZX 50 Index12,791.9267.10-0.52%
S&P 5006,225.524.46-0.07%
S&P/ASX 2008,558.0032.70-0.38%
SSE Composite Index3,507.6910.220.29%

Market Movers